Physician profile
Sheng Yi Wang
NPI 1649241902
$19,074.13
in general payments reported to CMS, 2019-2025
46 companies · $2,390 in 2025
The $2,390 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,259 · 2020: $2,288 · 2021: $2,773 · 2022: $3,045 · 2023: $3,422 · 2024: $2,898 · 2025: $2,390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,709.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,310.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $2,216.50 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $2,170.55 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,560.28 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,395.00 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $1,135.36 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $964.92 | 2019-2025 | Jardiance |
| Pfizer INC. | $931.50 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $681.22 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $630.99 | 2019-2025 | |
| Abbott Laboratories | $525.51 | 2021-2025 | Freestyle Libre 3, Afinion 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $344.59 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $340.81 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Dexcom, INC. | $331.92 | 2021-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $271.98 | 2022-2025 | Rexulti |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheng Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.